Forte Biosciences $150M Public Offering
Analysis based on 7 articles · First reported Apr 08, 2026 · Last updated Apr 09, 2026
The public offering by Forte Biosciences is expected to provide approximately $150 million in gross proceeds, which will be used for working capital and funding clinical development. This capital infusion is generally positive for Forte Biosciences, as it supports its ongoing research and development activities, potentially leading to future growth in the biotechnology sector.
Forte Biosciences, a clinical-stage biopharmaceutical company, announced the commencement and subsequent pricing of a public offering of its common stock. The offering involves 5,709,936 shares at $26.27 per share, with an expected gross proceeds of approximately $150 million. Forte Biosciences also granted the underwriters, including Guggenheim Partners and Barclays, a 30-day option to purchase up to an additional 856,490 shares. The net proceeds from this offering are intended to fund working capital, clinical development of its product candidate FB102, and other research activities. The offering is being made pursuant to a Registration Statement on Form S-3 filed with and declared effective by the United States — United States Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard